Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

NB4168

Source date not recordedAnalyse record ↗

Preclinical oral candidate designed to increase nicotinamide riboside exposure for a rare accelerated-aging disorder involving DNA repair and mitochondrial dysfunction.

Modality
oral nicotinamide-riboside-derived small molecule
Availability (US)
Preclinical; IND-enabling work announced for 2026
Biomarkers
nicotinamide riboside exposure; NAD+ metabolism; pharmacokinetics; neurological measures
Hallmark targeted
mitochondrial dysfunction, genomic instability, deregulated nutrient sensing
Kind
investigational drug